HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04619004. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Study identification
- NCT ID
- NCT04619004
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 277 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2021 (Actual)
- Primary completion
- Nov 21, 2022 (Actual)
- Completion
- Jan 4, 2027 (Estimated)
- Last update posted
- Sep 1, 2026
2021 – 2027
United States locations
- U.S. sites
- 33
- U.S. states
- 16
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| City of Hope | Duarte | California | 91010 | — |
| Moores Cancer Center at the UC San Diego Health | La Jolla | California | 92093 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California at Irvine | Orange | California | 92868 | — |
| Cedars Sinai | West Hollywood | California | 90048 | — |
| University of Colorado Denver - Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Memorial Healthcare System | Pembroke Pines | Florida | 33021 | — |
| Florida Cancer Specialist-North | St. Petersburg | Florida | 33770 | — |
| Florida Cancer Specialists-Panhandle | Tallahassee | Florida | 32308 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Florida Cancer Specialists-East | West Palm Beach | Florida | 33401 | — |
| Emory University | Dunwoody | Georgia | 30338 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Maryland - Marlene and Stewart Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital (MGH) - Hematology/Oncology | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center, Harvard Medical School | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Cancer Institute/Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Cleveland Clinic - Main Campus | Cleveland | Ohio | 44195 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Sarah Cannon Research Institute at Tennessee Oncology - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| University of Virginia Cancer Center - Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22903 | — |
| Virginia Cancer Specialist, PC | Fairfax | Virginia | 22031 | — |
| University of Washington/Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04619004, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04619004 live on ClinicalTrials.gov.